{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:43:06Z","timestamp":1793241786088,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtha.2024.11.015","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:27:45Z","timestamp":1732879665000},"page":"1483-1495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Deconstructing the ISTH hemophilia guidelines for the clinician"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Prasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.11.015_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.11.015_bib2","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1097\/HS9.0000000000000911","article-title":"Nonfactor therapies for hemophilia","volume":"7","author":"Young","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtha.2024.11.015_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17474086.2023.2184341","article-title":"New directions to develop therapies for people with hemophilia","volume":"16","author":"Gogia","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/hae.14588","article-title":"Building the blueprint: formulating a community-generated national plan for future research in inherited bleeding disorders","volume":"28","author":"Valentino","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"Rayment","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors","volume":"15","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib7","series-title":"Nordic haemophilia guidelines updated June","year":"2022"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.11.015_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib9","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Hemostasis clinical practice guideline for the treatment of hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib10","series-title":"Clinical practice guidelines we can trust","year":"2011"},{"key":"10.1016\/j.jtha.2024.11.015_bib11","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.jtha.2024.06.003","article-title":"Evidence, what\u2019s in a name? Some methodologic remarks on the Grading of Recommendations Assessment, Development, and Evaluation approach for guideline development","volume":"22","author":"Dekkers","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jth.15676","article-title":"Joint status of patients with nonsevere hemophilia A","volume":"20","author":"Zwagemaker","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/ejh.13763","article-title":"Pain and functional disability amongst adults with moderate and severe haemophilia A from the Irish personalized approach to the treatment of haemophilia (iPATH) study","author":"Kennedy","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/hae.14222","article-title":"Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors","volume":"27","author":"Kempton","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib15","first-page":"1334","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.11.015_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/hae.14851","article-title":"Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen","volume":"29","author":"Okolo","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.11.015_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hae.14353","article-title":"Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: illustrative real-world cases to support shared decision-making","volume":"27","author":"Mason","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/hae.13461","article-title":"Intracranial hemorrhage in children with inherited bleeding disorders in the UK 2003-2015: a national cohort study","volume":"24","author":"Chalmers","year":"2018","journal-title":"Haemophilia"},{"issue":"Suppl 5","key":"10.1016\/j.jtha.2024.11.015_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13028","article-title":"Extended half-life clotting factor concentrates: results from published clinical trials","volume":"22","author":"Young","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa2312611","article-title":"Efanesoctocog alfa prophylaxis for children with severe hemophilia A","volume":"391","author":"Malec","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/hae.14785","article-title":"Low dose emicizumab prophylaxis in haemophilia A patients: a pilot study from India","volume":"29","author":"Bansal","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/hae.14707","article-title":"Effectiveness of monthly low dose prophylaxis without 4-week loading doses among patients with hemophilia A with and without inhibitors: a case series report","volume":"29","author":"Chuansumrit","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14968","article-title":"Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries","volume":"30","author":"Mannucci","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.11.015_bib30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib31","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib33","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A\u00a0multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jim\u00e9nez-Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102265","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 previously untreated patients from Europe and Canada","volume":"7","author":"Fischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib38","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2352-3026(18)30048-6","article-title":"Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of a 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort","volume":"5","author":"Feldman","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.11.015_bib39","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.11.015_bib40","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse-Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.11.015_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2516.2007.01442.x","article-title":"Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors","volume":"13","author":"Leissinger","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib47","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib48","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.transci.2019.08.008","article-title":"Hemophilia A with inhibitor: immune tolerance induction (ITI) in the mirror of time","volume":"58","author":"Nakar","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2024.11.015_bib49","first-page":"45","article-title":"The German Registry of immune tolerance treatment in hemophili--1999 update","volume":"85","author":"Lenk","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.11.015_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2516.2001.00469.x","article-title":"Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry","volume":"7","author":"Haya","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib52","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/jth.15342","article-title":"Management of children with hemophilia A: how emicizumab has changed the landscape","volume":"19","author":"Young","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib53","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/hae.14418","article-title":"PERSEPT 3: a phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors","volume":"27","author":"Esocbar","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 \u03bcg kg\u22121-dose rFVIIa vs. standard 90 \u03bcg kg\u22121-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.11.015_bib58","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/hae.13301","article-title":"PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding","volume":"23","author":"Wang","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib59","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/hae.14563","article-title":"Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric patients (<12 years) with haemophilia A or B with inhibitors","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hae.14253","article-title":"Exploratory in\u00a0vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma","volume":"27","author":"Grandoni","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib62","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-a critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib63","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib64","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.11.015_bib65","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.11.015_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/hae.14999","article-title":"Unresolved hemostasis issues in haemophilia","volume":"30","author":"Sidonio","year":"2024","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2024.11.015_bib67","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13489","article-title":"Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes","volume":"24","author":"Pierce","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.11.015_bib68","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.11.015_bib69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.11.015_bib70","article-title":"Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or svere hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial","volume":"7","author":"Cuker","year":"2023","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624007050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:37:08Z","timestamp":1777639028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624007050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1538783624007050"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.11.015","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deconstructing the ISTH hemophilia guidelines for the clinician","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}